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ABSTRACT
Background & objectives: Leishmaniasis is a growing health problem in many parts of the world. Efforts to find
new chemotherapeutics for leishmaniasis remain a priority. This study was carried out to determine the effect of
combination and monotherapies using plant extracts and herbicides on Leishmania major infection in BALB/c
mice.
Methods: The herbicides and saponin extract were purchased from Sigma. Roots of Plumbago capensis were
collected from Karura forest, Nairobi, Kenya. Plant extractions were done in KEMRI at Center for Traditional
Medicines and Drugs Research.
Results: Lesion sizes after infection of BALB/c mice were similar in all the experimental groups till the onset of
therapeutic treatments (p >0.05). At 15 days post-treatment, significant differences (p < 0.05) were discerned in
the lesion sizes of the BALB/c mice in all the mono- and combined-treated groups. However, the combined
therapies caused total elimination of the parasites from the lesions and significantly reduced parasite burden in
liver and spleen compared to the untreated controls at the end of the experiment.
Interpretation & conclusion: The results of this study demonstrate that combination therapy using alternative
administration of saponin, acriflavine, trifluralin and plumbagin is effective in treating L. major infection in
mice. In this regard, an investigation into the efficacy of these combined therapies against other Leishmania
strains should be explored further. Furthermore, studies with these combination therapies should be done on
non-human primates such as the vervet monkey (Cercopithecus aethiops).
Key words   Antileishmanial activity; herbicides; Leishmania major; plant extracts
INTRODUCTION
Leishmaniasis is a zoonotic disease of major public
health and veterinary importance, affecting 88 countries
with at least two million new cases each year and 367
million people at risk1. It is caused by the protozoan para-
site of the genus Leishmania and transmitted to the mam-
malian host by the bite of the phlebotomine sandfly. Com-
plicated clinical symptoms range from the skin lesions of
cutaneous leishmaniasis (CL) to the fatal visceral leish-
maniasis (VL), making the disease an important health
problem in the world. Leishmania parasite has a complex
life cycle that includes two different developmental forms.
The parasites replicate as promastigotes and develop into
infective metacyclic promastigotes in the sandfly vector,
and the infective promastigotes invade the macrophages
and differentiate into amastigotes in the mammalian host2.
Since vaccines against leishmaniasis are not available,
the control of this disease depends on prompt diagnosis
and chemotherapy on infected humans and dogs. Chemo-
therapy of this disease has relied mainly on pentavalent
antimonials, amphotericin B (AMB), and pentamidine3.
These drugs are toxic and difficult to administer because
of their long-term treatment and high cost4,5. Though tar-
geting of antileishmanial agents in liposomes,
microspheres, and nanoparticles can successfully increase
the efficacy and reduce toxicity of antileishmanial drugs,
the limitations of these delivery strategies include non-spe-
cific accumulation of reticuloendothelial system (RES),
instability of the liposomal formulations, and the incom-
plete degradation of polymeric delivery systems6. There-
fore, investigations are still in progress to discover new
antileishmanial drugs.
Mitotic disrupter herbicides like trifluralin are good
lead compounds for antiparasitic drugs because these have
already been shown to lack activity against mammalian J Vector Borne Dis 49, September 2012 124
cells and are inexpensive to produce. Trifluralin acts di-
rectly with the major microtubule protein, tubulin, lead-
ing to disruption of mitosis. Leishmania species also ap-
pear to have the same biochemical mechanism of inhibition
as plants, since trifluralin was found to specifically in-
hibit polymerization of Leishmania tubulin, but not mouse
tubulin, in vitro7. Thus, leishmanial tubulin appears to be
more similar to plant tubulin than to mammalian tubulin,
with distinct structures that can be targeted by drugs. Al-
though, the antimicrobial dinitroaniline herbicides show
great potential as antiprotozoal compounds, disputed in-
dications of potential carcinogenecity will probably keep
trifluralin from being developed for human use. However,
in 1993 Chan and his co-workers indicated that an impu-
rity contaminant in trifluralin, not trifluralin itself, may
be responsible for the observed in vitro activity against
Leishmania species8. The active impurity in trifluralin is
chloralin, an intermediate in the synthesis of trifluralin.
However, there is no commercial impetus to reformulate
this drug.
On the basis of ultrastructural morphology and se-
quence comparison of small subunit ribosomal RNAs,
Leishmania and Trypanosoma are phylogenetically related
and both species have a kinetoplast that contains superhe-
lical DNA9. As early as 1968, Simpson10 showed that ac-
riflavine in low concentrations, through selective inhibi-
tion of replication of kinetoplast DNA and not nuclear
DNA is able to induce dyskinetoplasia in cultures of L.
tarentolae. During growth in acriflavine cultures, cells
were seen to exhibit an increasing impairment of colony-
forming ability and rate of respiration. It was suggested
that the mechanism of action could be photo-oxidization
of the kinetoplast DNA. It is, therefore, possible that acri-
dine compounds, either modified or used in combination
with other drugs can be used to treat the leishmaniases.
Saponins on the other hand are high molecular weight
glycosylated plant secondary metabolites, consisting of a
sugar moiety linked to a triterpene or steroid aglycone that
show various kinds of biological activity and have been
used widely as anti-inflammatory, antitumor, anti-HIV,
and antifungal agents11. Consequently, triterpenoid sapo-
nin structures have become the synthetic targets of many
research groups12. Detergent properties are the typical
characteristics of saponins. These produce stable foam
when dissolved in water, which is why some saponin-con-
taining plants have been used as soaps for hundreds of
years. Saponin containing plants are used as traditional
medicines, especially in Asia, and are intensively used in
food, veterinary and medical industries13. Antileishmanial
activity has been reported for Hedera, Dracaena and Yucca
saponins14, but their value as drug candidates has not been
fully assessed. Saponins inhibit the growth of the
promastigote forms by acting on the membrane of the para-
site where they induce a drop in membrane potential15.
Plumbagin (2-methoxy-5-hydroxy-1,4-naphtho-
quinone) is a natural naphthoquinone possessing various
pharmacological activities such as antimalarial16, antimi-
crobial17, anticancer18, cardiotonic19 and antifertility ac-
tion20. At present, the most exploited source of plumbagin
is the roots of Plumbago spp. (Plumbago europea, P.
rosea, P. zeylanica and P. capensis). However, these plants
grow quite slowly and it takes long before the roots are
suitable for use21. In this study, the roots of P. capensis
were used for plumbagin extraction. Therefore, there is
need to search for alternative sources of plumbagin that
grow quickly.
Advances in antileishmanial chemotherapy including
development of new drugs have made combination che-
motherapy a real possibility. Drug combinations aim to
delay or prevent the emergence of resistance, shorten the
course of treatment and lower required doses. Other po-
tential advances include convenience, better compliance
and lower costs22.  In this study, trifluralin, acriflavine,
saponin and plumbagin were used in alternate combina-
tion of two drugs against L. major infection BALB/c mice.
MATERIAL & METHODS
Leishmania parasites
Metacyclic promastigotes of L. major (IDUB/KE/83=
NLB-144 strain) were used. This strain has been main-
tained by cryopreservation and in vitro culture, and peri-
odic passage in BALB/c mice at Kenya Medical Research
Institute (KEMRI). Parasites were grown at 26oC in
Schneider’s Drosophila medium supplemented with 10%
(v/v) heat-inactivated fetal calf serum (FCS).
Mice
Female BALB/c mice ranging from 8-12 wk old were
used in this study. They were strictly maintained under
the rules and regulations of the Animal Care and Use Com-
mittee-KEMRI (ACUC-KEMRI, Kenya) in specific patho-
gen-free conditions with laminal air flow. All mice were
inoculated intramuscularly with 2 × 106 stationary phase
promastigotes of L. major on the left hind footpad (LHFD).
All animal experiments were approved by the Kenya Medi-
cal Research Institute (KEMRI) Committee. Lesion sizes
were estimated weekly for 2.5 months post-infection. In-
fected control mice were not treated. In order to compare
the effect of the drug, the difference between the infected
left hind footpad and the right hind footpad was taken on
a weekly basis according to the method of Nolan and 125 Makwali et al: Therapy of Leishmaniasis
Farrell23. Briefly, the lesion size was measured in two di-
mensions (D and d) at right angles to each other with a
caliper gauge, and the lesion size(s) determined by the fol-
lowing formula: S = (D × d)/2. The mice were anesthe-
tized with sodium thiopental (50 g/g of body weight) and
sacrificed at the end of the experiment and their spleen
and liver were removed for parasite load determination.
This was done because L. major infection in BALB/c
visceralises.
Drug administration
After the skin lesion was confirmed (two months after
the inoculation), the infected mice were randomly assigned
to seven groups of 10 mice each. The drugs were subcuta-
neously injected into the mice twice daily for seven days
in different schemes of drug combinations with a drug con-
centration equivalent to the IC50/24 h of each of the six
drugs used. In some cases the treatment was withheld up
to four months to evaluate the efficacy of the treatment in
advanced infection. For the experimental handling, the
groups had been divided as follows: Group 1 received a
dose each of acriflavine and saponin; Group 2 received a
dose each of trifluralin and acriflavine; Group 3 received
a dose each of trifluralin and plumbagin; Group 4 received
a dose each of saponin and plumbagin; Group 5 received
a dose each of trifluralin and saponin; and Group 6 re-
ceived a dose each of acriflavine and plumbagin. The con-
trol group was left untreated. Similar groupings were set
up for monotherapy treatments.
Drugs and plant extracts
Trifluralin, acriflavine and saponin extract were pur-
chased from Sigma. Roots of P. capensis were collected
from Karura forest, Nairobi, Kenya. Plant extractions were
done in KEMRI at Center for Traditional Medicines and
Drugs Research. Reference drugs included sodium
stibogluconate (Pentostam; Sigma), pentamidine
isethionate (Sigma), and amphotericin B (AMB)
(Fungizone; Squib).
Extract preparation
Roots of P. capensis were oven dried at 40°C and
powdered (5 mm of particle dia). The plant (9.5 g) was
extracted with 300 ml of chloroform in the Soxhlet appa-
ratus for 5 h to obtain high percentage of plumbagin. All
the solutions were evaporated to dryness under reduced
pressure. The extraction efficiency was defined as follows:
        Mass of extracts
    Mass of extraction = × 100
            Mass of dried material roots
Compounds used in this study
Plant extract solutions for biological testing and the
reference drugs were prepared in 100% dimethyl sulfox-
ide (DMSO) at 20 mg/ml. Reference drugs included so-
dium stibogluconate (Pentostam; Sigma), amphotericin B
(Fungizone; Squib), pentamidine isethionate (Sigma), tri-
fluralin (Sigma) and acriflavine (Sigma). All the prepared
drugs were stored at 4oC and retrieved only during use. In
most experiments, pentostam was used as a reference drug.
Determination of parasite burdens
The assessment of the amastigote burden was carried
out by blinded microscopic enumeration with Giemsa-
stained liver and spleen touch prints. The total amastigote
burdens were calculated as Leishman Donovan units
(LDU, number of amastigotes per 1000 nucleated cells ×
organ weight [in grams] × 2 × 105), according to Stauber’s
formula24. The percent efficacy was calculated as [1–
(mean amastigote load in treated mice/mean amastigote
load in NTC)]×100. An LDU reduction of at least 80%
was adopted as the minimal criterion for drug efficacy.
Collection of target organs and determination of amastigote
burdens were not done for mice that succumbed due to
severe clinical disease.
Statistical analysis
All the experiments were carried out thrice. The mean
and standard deviation of at least three experiments were
determined. Statistical analysis of the differences between
mean values obtained for the experimental groups was done
by analysis of variance (ANOVA) and Student’s t-test. P-
values of 0.05 or less were considered significant.
RESULTS
Effect of monotherapy on L. major lesion development
BALB/c mice infected on the LHFD with L. major
promastigotes showed skin lesions as a single nodule with
or without ulceration two months after inoculation. The
lesions developed to full size in most of the infected mice.
Efficacy of monotherapy treatments on the development
of lesion sizes in BALB/c mice is presented in Fig. 1. Le-
sion sizes after infection of the BALB/c mice were similar
in all the treatment groups till the onset of therapeutic treat-
ments. Treatment was started after two months of infec-
tion. At 15 days post-treatment, significant differences were
discerned in the lesion sizes of the BALB/c mice. BALB/c
mice-treated using acriflavine and trifluralin produced sig-
nificantly larger lesion sizes than those being treated us-
ing saponin and plumbagin. However, after one month of
monotherapy treatment, lesion sizes in all the BALB/c mice J Vector Borne Dis 49, September 2012 126
Table 1. Effects of monotherapy treatment on L. major infection in BALB/c mice
Body wt (g) Days post- Relative weight (%) †                                      LDU (106) (% efficacy)‡
infection
Liver Spleen Liver       Spleen
Treatment groupa
Plumbagin 25.8 ± 0.7 8 4.3 ± 0.29 0.46 ± 0.07 11.72 ± 0.2 (98.8)   0.53 ± 0.08 (97.6)
Saponin 24.5 ± 0.5 8 4.2 ± 0.31 0.43 ± 0.06 13.23 ± 0.3 (97.8) 0.52 ± 0.07 (97.6)
Trifluralin 25.9 ± 0.8 8 5.2 ± 0.17 0.58 ± 0.1 20.25 ± 0.44 (86.4) 0.63 ± 0.5 (84.1)
Acriflavin 25.5 ± 0.5 8 5.6 ± 0.12 0.59 ± 0.25 22.06 ± 0.35 (85.4) 0.69 ± 0.3 (83.3)
Pentostam (250 mg/kg) 26 ± 2.8 8 4.4 ± 0.24 0.45 ± 0.23 11.98 ± 0.52 (98.6) 0.56 ± 0.11(95.6)
NTC 24.5 ± 1.4 8 6.75 ± 2.19 0.69 ± 0.08 149.3 ± 12.84 3.18 ± 0.25
Treatment groupb
Plumbagin 17.4 ± 0.7 35 6.45 ± 0.55 0.69 ± 0.09 5.63 ± 0.48 (99.6) 0.51 ± 0.08 (97.4)
Saponin 18.1 ± 0.7 35 5.69 ± 0.59 0.58 ± 0.08 3.23 ± 0.28 (99.9) 0.56 ± 0.07 (97.6)
Trifluralin 16 ± 0.8 35 9.60 ± 0.55 1.10 ± 0.18 102.59 ± 0.45 (93.1) 0.48 ± 0.54 (84.1)
Acriflavin 15.5 ± 0.5 35 9.26 ± 0.31 1.18 ± 0.05 13.66 ± 0.30 (90.8) 0.37 ± 0.14 (78.6)
Pentostam (250 mg/kg) 17.2 ± 0.5 35 4.52 ± 0.22 0.45 ± 0.22 0 ± 0 (100)
NTC 17.5 ± 0.6 35 7.01 ± 0.4 1.3 ± 0.3 746.5 ± 80.54
Plumbagin 17 ± 0.56 56 5.17 ± 0.9 0.39 ± 0.12 11.28 ± 1.3 (92.44) 1.51 ± 0.14 (83.9)
Saponin 18.3 ± 1.54 56 5.32 ± 0.63 0.52 ± 1.4 27.24 ± 2 (92.06) 1.48 ± 0.21 (86.8)
Trifluralin 16 ± 1.67 56 5.3 ± 0.85 0.32 ± 0.05 29.47 ± 3.1(82.40) 2.73 ± 0.11 (77.0)
Acriflavin 15 ± 2.09 56 4.18 ± 0.30 0.39 ± 0.08 38.4 ± 4.25 (80.44) 3.06 ± 0.18 (66.7)
Pentostam (250 mg/kg) 17 ± 0.57 56 6.25 ± 1.68 0.82 ± 0.88 11.85 ± 3.65 (92.1) 2.84 ± 0.68 (73.6)
NTC 17.5 ± 1.2 56 8.03 ± 0.91 2.01 ± 0.41 597.2 ± 75.7 12.51 ± 6.01
Plumbagin 14 ± 0.98 – ND
Saponin 15 ± 0.78 63 ND
Trifluralin 14 ± 0.65 63 ND
Acriflavin 15 ± 0.74 63 ND
Pentostam (250 mg/kg) 15 ± 0.54 84 6.31 ± 0.92 1.25 ± 0.58 ND ND
NTC 13 ± 0.75 84 –
aTreatment of acute infection on Day 1 post-infection at 0.2 mg/kg;  bTreatment of chronic infection on Day 28 post-infection at 1.25 mg/kg;
†Organ weight/body weight; ‡[1-(mean amastigote load in treated mice/mean amastigote load in NTC)] × 100; NTC —Non-treated control;
LDU—Leishman Donovan units; ND — Not done.
Fig. 1: Lesion sizes of mice during infection, pre- and post-
monotherapeutic treatments.
had differentiated (p < 0.05) with saponin maintaining sig-
nificantly lower lesion size in the BALB/c mice. Lesions
were completely eliminated after monotherapeutic treat-
ment using saponin after two months post-treatment while
all the other monotherapy treatments reduced the lesions
after four months post-treatment.
Effects of monotherapy on liver and spleen parasite
burdens
A single 0.2 mg/kg dose of saponin, plumbagin, tri-
fluralin and acriflavine resulted in 97.8, 98.8, 86.4 and
85.4% reductions in liver amastigote burden on Day 7
post-treatment, respectively, whereas on Day 56 post-treat-
ment the liver amastigote burden in mice-treated with sa-
ponin, plumbagin, trifluralin and acriflavine were 92.06,
92.44, 82.42 and 80.44%, respectively. The severity of
infection in the non-treated controls (NTC) increased dra-
matically between Day 7 and Day 56, as illustrated by a
4-fold increase in the liver amastigote burden (from 149.3 ×
106 LDU on Day 7 to 597.2 × 106 LDU on Day 56) (Table
1). Despite the apparently adequate parasite control by
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the test compounds at 0.2 mg/kg (80.44–92.44% reduc-
tion in liver amastigote burden), deaths did occur and the
survivors showed considerable weight loss (52%). Treat-
ment with the test compounds at 1.25 mg/kg resulted in a
high reduction in liver amastigote burden. However, one
animal died on Day 46 and the overall body weight gain
was low (5–7 g). By Day 35, control mice already showed
liver infection (746.5 × 106 LDU), poor health status, and
a body weight loss of about 25%. Control of liver infec-
tion was obtained with saponin at 0.8 mg/kg and pentostam
at 250 mg/kg/body weight, with 99.9 and 99.4% reduc-
tions within 7 days of treatment, respectively; and control
of liver infection was obtained with plumbagin, trifluralin
and acriflavine at 1.25 mg/kg with 99.6, 93.1 and 90.8%
reductions within 7 days of treatment, respectively. How-
ever, a net body weight loss was noted in all the animals,
and the spleen remained positive for amastigotes.
Effect of combination therapy on L. major lesion devel-
opment
In the initial testing for the antileishmanial activity of
independent drugs the order of potency was as follows in
decreasing strength: saponin (Sap) >Plumbagin (Plgn) >
Trifluralin (Tri) > Acriflavine (Acri).  After 7 days of
treatment, twice daily with saponin, the parasites in all the
infected animals disappeared from the lesion area after 14
accumulated drugging, and the open lesions completely
healed in a period of 30 days (Fig. 1). In the independent
drug therapy (monotherapy), the parasites reappeared in
the skin at the site of infection and in the surrounding skin
area 90 to 150 days after the end of the treatment. It was
a result of a successful combination of acriflavine and
saponin that prompted the following series of experiments.
Each drug combination was examined. In this case the
lesions healed, with only the untreated mice dying.
Loss of weight and discoloration was apparent in un-
treated mice and mice treated with the drugs of choice
namely AMB and pentostam. The treated mice, on the
other hand, increased in weight. Of the six drugs of choice
tested against the disease, sodium stibogluconate and pen-
tamidine were effective but some mice treated with these
drugs of choice died as a result of toxicity. None of the
mice treated with combination therapy died. No formula-
tion was toxic to the experimental mice. Combination treat-
ment comprising of alternate administration of test com-
pounds caused total elimination of the parasites from the
lesion at the end of the treatment (Fig. 2). After 7 days of
treatment, twice daily, with these combinations, the para-
sites in all the infected animals disappeared from the le-
sion area, and the open lesion completely healed in a pe-
riod of 30 days.
Efficacy of combined treatments on the development
of lesion sizes in BALB/c mice is presented in Fig. 2. Le-
sion sizes after infection of the BALB/c were similar in all
the treatment groups till the onset of therapeutic treatments
(p >0.05). Treatment was started after two months of
infection. At 15 days post-treatment, significant differ-
ences (p <0.05) were discerned in the lesion sizes of the
BALB/c mice. BALB/c mice being treated using acrifla-
vine/plumbagin produced significantly larger lesion sizes
than those being treated using acriflavine/saponin. How-
ever, after one month of monotherapy treatment, lesion
sizes in all the BALB/c mice had differentiated (p < 0.05)
with acriflavine/saponin maintaining significantly lower
lesion size in the BALB/c mice. Lesions were completely
eliminated after combination treatment using acriflavine/
saponin after one and half months post-treatment, while
all the rest of the combinations cleared the lesions after
two months post-treatments, except for acriflavine/plum-
bagin treatment that reduced lesions after four months post-
treatment.
Effects of combined treatments on the amastigote liver
and spleen burdens
Results of therapeutic treatments on the liver and
spleen LDU are presented in Fig. 3. For both the liver and
spleen, the non-treated controls (NTC) had the highest
LDU whereas there was a decline in the LDU of the liver
from Day 10 to 52, the LDU increased during the same
time period. After 10, 30 and 52 days of treatments, sig-
nificantly (p <0.05) higher LDU in the liver and spleen
occurred in acriflavine/plumbagin combination followed
by trifluralin/plumbagin and the lowest LDU occurred in
the trifluralin/acriflavine combination therapies.
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DISCUSSION
Leishmania major, the aetiological agent of CL on
humans, is a parasite of the skin. However, in the BALB/c
mice, L. major produces visceral infection in addition to
the local lesion at the point of inoculation. Thus, it was a
suitable model for this study. The fact that a spontaneous
healing cannot be achieved in these mice indicates that the
complete healing of the lesions is due to the combination
therapy administered only. Therefore, to better evaluate if
the drugs effectively reduced the parasites burden in the
liver and spleen after treatment, short-term and long-term
efficacies for the mono and combination therapies were
determined. For both the liver and spleen, the non-treated
controls had the highest LDU. Significantly (p <0.05)
higher parasite load in the liver and spleen occurred in
acriflavine/plumbagin combination followed by triflura-
lin/plumbagin and the lowest LDU occurred in the triflu-
ralin and acriflavine combination therapies.
These results indicate that acridine and dinitroaniline
herbicides with the plant extracts are promising lead com-
pounds for development as novel antileishmanial agents.
DMSO was used in all the drug formulations because it
has been reported to increase drug penetration25. Com-
bined therapy of saponin and acriflavine was the most ef-
fective in reducing both the lesion sizes and hepatic para-
site load; followed by saponin & plumbagin; trifluralin &
acriflavine; trifluralin & saponin; trifluralin & plumbagin
and acriflavine & plumbagin combinations.  These com-
binations were used in two doses injected in mice previ-
ously infected with L. major and having pentostam as ref-
erence drug. The significant decrease in the lesion sizes in
the combined therapy is indicative of the occurrence of a
synergistic mechanism between the drug combinations. It
is interesting to note that the combined administration of
saponin and other test drugs significantly (p <0.05) re-
duced footpad size and concomitantly significantly inhib-
ited parasite growth. This is attributable to the main bio-
logical activity ascribed to saponins: their membrane
permeabilizing property. Saponin enhanced the uptake of
the other drugs, thus, increasing their activity against the
parasites.
There was a remarkable long-term in vivo activity of
trifluralin, acriflavine, saponin and plumbagin at 1.25 mg/
kg dosage administered subcutaneously against established
L. major infection in BALB/c mice. The optimal dose used
with the test compounds was 500 g/ml. At 500 g/ml
per kg of body weight daily for seven days showed a high
short-term efficacy against recent infection of L. major.
For the sake of completeness, since a direct extrapolation
of the drug doses from mice to humans is unreliable, it
should be noted that in Leishmania therapy the recom-
mended therapeutic dose of pentostam on humans has been
established to be 20 mg/kg of body weight/day for 20
days26. The short-term efficacy of the test compounds
against a Leishmania infection which evolved for two
months prior to drug administration was demonstrated.
This phase of murine cutaneous leishmaniasis caused by
L. major corresponds to the end of the acute phase of the
disease27 and was characterized in this study as demon-
strated by other researchers by a spontaneous decrease of
the hepatic and a steady increase of the splenic parasite
burden (Fig. 3)28.
The amastigote loads were significantly lower in de-
creasing order in the spleens and livers of saponin, plum-
bagin, trifluralin and acriflavine-treated mice respectively
than in those of the controls at all the time points tested.
Moreover, the progression of the splenomegaly and the
increase of the splenic load were found to be significantly
lower in treated mice than in controls, demonstrating that
parasite suppression and the inhibition of growth persisted
for at least 7 to 8 wk after the end of the drug uptake.
Although data in this study do not provide a direct
measure of the parasite killing 1-[amastigote load at the
end of the treatment/amastigote load before the start of
Fig. 3: Liver and spleen LDU on Day 10, 30 and 52 post-treatment.
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the treatment], these show induction of effective
leishmanicidal activity. The spleen is a major site of Leish-
mania multiplication in the natural infection in suscep-
tible hosts. In BALB/c mice, the splenic parasite burden
is initially quite low, but it increases steadily for at least
three months, and unlike the hepatic burden, it does not
decline spontaneously without treatment29. The splenic ef-
ficacy of the test compounds should be emphasized, since
until recently splenectomy was performed as the last re-
course for cases of antimony resistant leishmaniasis. The
efficacy of the test compounds in the spleen is compatible
with the available data on its tissue distribution30. The
prolonged effect of the test compounds on parasite growth
suggests a low catabolism and/or slow clearance, result-
ing in a long biological half-life of the drugs.
From the results of this study, it is evident that combi-
nation therapy was highly effective in both healing the
lesion and eliminating the parasites from the liver and
spleen at low drug concentration (500 g/ml) as opposed
to monotherapy at 1.25 mg/kg. Total elimination of the
parasites was achieved after 7 days of treatment of both
early and advanced infections. Furthermore, this duration
of treatment was sufficient to clear the lesion of both the
leishmanial parasites and the secondary infection, mainly
bacterial, accompanying this disease. In monotherapy treat-
ment, parasites reappeared at the site of inoculation many
months later after the termination of treatment. On the
other hand, in combination treatments, no reappearance
of parasites at the site of infection ever occurred. This
implies that monotherapy did not achieve total clearance
of parasites, hence, the relapse. In contrast, combination
therapy caused elimination of parasites in the internal or-
gans. It can, therefore, be concluded that administration
of the combination of drugs is effective and superior than
individual drugs. The synergism shown with the combined
drugs brings us to the concept of structure-function ap-
proach in fighting leishmaniasis. In 1993, Marion and oth-
ers reported that higher efficacy may be correlated with
molecular structural features of compounds under study31.
This is the first time a novel antileishmanial activity in the
plumbaginacea extract and triterpenoid saponin extract in
combination with acridine and dinitroaniline herbicides has
been reported.
CONCLUSION
Combination therapy with plumbaginacea extract and
triterpenoid saponin extract in combination with acridine
and dinitroaniline herbicides resulted in complete clear-
ance of parasitemia from both the lesion site and internal
organs (the livers and spleens) of L. major-infected BALB/c
mice. On the basis of these results and considered together
with existing studies that have been reported on the safe
doses and side effects of combination drug therapy, and
its administration by the subcutaneous route, combina-
tion therapy is a promising approach for the treatment of
L. major infection.
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